rs10956445 - CCDC26
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-Wide Data reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases - Unknown journal (n.d.) · Unknown authors · PubMed 24709693
ABSTRACT: Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to targeted treatment. We genotyped 759 JIA cases from the UK, Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of treatment. In Phase I analysis samples were analysed for association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P<1×10−5): three contain genes o
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
methotrexate response prediction with rheumatologist Moderate
rs10956445 C-allele carriers show significantly improved methotrexate response and lower active joint counts in juvenile idiopathic arthritis
If diagnosed with JIA or prescribed methotrexate, share this genetic result with your rheumatologist